These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17430171)

  • 1. Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential.
    Hill JM
    Curr Pharm Des; 2007; 13(11):1079-89. PubMed ID: 17430171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VIP in neurological diseases: more than a neuropeptide.
    Morell M; Souza-Moreira L; González-Rey E
    Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):323-32. PubMed ID: 23094829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.
    White CM; Ji S; Cai H; Maudsley S; Martin B
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):661-6. PubMed ID: 20632962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VIP regulation of embryonic growth.
    Hill JM; McCune SK; Alvero RJ; Glazner GW; Brenneman DE
    Ann N Y Acad Sci; 1996 Dec; 805():259-68; discussion 268-9. PubMed ID: 8993408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos.
    Gressens P; Hill JM; Gozes I; Fridkin M; Brenneman DE
    Nature; 1993 Mar; 362(6416):155-8. PubMed ID: 8383805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide.
    Spong CY; Lee SJ; McCune SK; Gibney G; Abebe DT; Brenneman DE; Hill JM
    Ann N Y Acad Sci; 1999; 897():101-8. PubMed ID: 10676439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring.
    Hill JM; Cuasay K; Abebe DT
    Exp Neurol; 2007 Jul; 206(1):101-13. PubMed ID: 17521630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: vasoactive intestinal peptide (vip): historic perspective and future potential.
    Foster N
    Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):303-7. PubMed ID: 23094826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.
    Smalley SG; Barrow PA; Foster N
    Clin Exp Immunol; 2009 Aug; 157(2):225-34. PubMed ID: 19604262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.
    Gressens P; Hill JM; Paindaveine B; Gozes I; Fridkin M; Brenneman DE
    J Clin Invest; 1994 Nov; 94(5):2020-7. PubMed ID: 7962548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
    Gonzalez-Rey E; Varela N; Chorny A; Delgado M
    Curr Pharm Des; 2007; 13(11):1113-39. PubMed ID: 17430175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent.
    Hill JM; McCune SK; Alvero RJ; Glazner GW; Henins KA; Stanziale SF; Keimowitz JR; Brenneman DE
    J Clin Invest; 1996 Jan; 97(1):202-8. PubMed ID: 8550835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.
    Hill JM; Hauser JM; Sheppard LM; Abebe D; Spivak-Pohis I; Kushnir M; Deitch I; Gozes I
    J Mol Neurosci; 2007; 31(3):183-200. PubMed ID: 17726225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide: an important trophic factor and developmental regulator?
    Waschek JA
    Dev Neurosci; 1995; 17(1):1-7. PubMed ID: 7621745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of vasoactive intestinal peptide in neurodegenerative disorders.
    Deng G; Jin L
    Neurol Res; 2017 Jan; 39(1):65-72. PubMed ID: 27786097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vasoactive intestinal peptide: a novel neurotrophic factor].
    Gressens P
    Arch Pediatr; 1998 Jun; 5(6):654-60. PubMed ID: 9759212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.
    Maduna T; Lelievre V
    J Neurosci Res; 2016 Dec; 94(12):1472-1487. PubMed ID: 27717098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide.
    Spong CY; Lee SJ; McCune SK; Gibney G; Abebe DT; Alvero R; Brenneman DE; Hill JM
    Endocrinology; 1999 Feb; 140(2):917-24. PubMed ID: 9927324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies.
    Gressens P; Paindaveine B; Hill JM; Brenneman DE; Evrard P
    Ann N Y Acad Sci; 1997 Apr; 814():152-60. PubMed ID: 9160967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
    Dietl MM; Hof PR; Martin JL; Magistretti PJ; Palacios JM
    Brain Res; 1990 Jun; 520(1-2):14-26. PubMed ID: 2169952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.